欢迎访问《微生物与感染》官方网站,今天是
特约专稿

毛霉病的防治策略与研究进展

  • 赵静宇1 ,
  • 2 ,
  • 方伟1 ,
  • 潘炜华1 ,
  • 廖万清1
展开
  • 1. 上海市医学真菌分子生物学重点实验室,上海长征医院皮肤科,上海 200003; 2. 上海东方肝胆外科医院皮肤科,上海 200438

收稿日期: 2021-06-15

  网络出版日期: 2021-10-25

基金资助

国家自然科学基金(82072259),上海市医学真菌分子生物学重点实验室基金(17DZ2272900)

Progress in prevention and management of mucormycosis

  • ZHAO Jingyu1 ,
  • 2 ,
  • FANG Wei1 ,
  • PAN Weihua1 ,
  • LIAO Wanqing1
Expand
  • 1. Shanghai Key Laboratory of Molecular Medical Mycology, Department of Dermatology, Shanghai Changzheng Hospital, Shanghai 200003, China; 2. Department of Dermatology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China

Received date: 2021-06-15

  Online published: 2021-10-25

Supported by

 

摘要

毛霉病是一种进展迅速、病死率高的罕见侵袭性真菌病,近年来其发病率呈整体上升趋势。自2019年12月以来,2019冠状病毒病(corona virus disease 2019,COVID-19)在全世界广泛流行并引发第六次国际公共卫生事件,在此背景下印度大规模暴发了毛霉病。本文就毛霉病流行病学、病原学、临床表现、诊断治疗等方面的研究进展进行综述。对于临床可疑毛霉病患者,应尽早完成影像学、真菌病原学及分子生物学检查,以期实现毛霉病的早期诊断、早期治疗,改善患者临床转归及预后。

本文引用格式

赵静宇1 , 2 , 方伟1 , 潘炜华1 , 廖万清1 . 毛霉病的防治策略与研究进展[J]. 微生物与感染, 2021 , 16(5) : 291 -297 . DOI: DOI:10.3969/j.issn.1673-6184.2021.05.001

Abstract

Mucormycosis is a rare invasive fungal disease with rapid progress and high fatality rate. In the past years, its incidence has shown an upward trend. Since December 2019, the corona virus disease 2019 (COVID-19) epidemic has been widespread worldwide and triggered the sixth international public health event. In this context, a large-scale outbreak of mucormycosis has occurred in India. This article reviewed the progress in the epidemiology, etiology, clinical manifestations, and diagnosis and treatment principles of mucormycosis. For the patients with suspected mucormycosis, imaging, fungal etiology, and molecular biological examinations should be completed as soon as possible, which are vital to realize early diagnosis and treatment and improve their clinical outcomes and prognosis.

参考文献

 
文章导航

/